Cell Therapy News Volume 22.01 | Jan 11 2021

May 12, 2022

107

CTN 22.01 | Jan 11 2021

Cell Therapy News by STEMCELL Technologies

Vol. 22.01 – 11 January, 2021

TOP STORY

Distinct
Developmental Pathways from Blood Monocytes Generate Human Lung Macrophage Diversity

Intravascular cell labeling, cell transplantation, and fate-mapping studies established that classical CD14⁺ blood monocytes derived from hematopoietic stem and progenitor cells migrated into lung tissue and gave rise to human interstitial and alveolar macrophages.
[Immunity]

Abstract Graphical Abstract

Explore scientific events this January with the Science Events Calendar.

PUBLICATIONSRanked by the impact factor of the journal

CXCR5
CAR-T Cells Simultaneously Target B Cell Non-Hodgkin’s Lymphoma and Tumor-Supportive Follicular T Helper Cells

To target both B cell Non-Hodgkin’s lymphoma and follicular T helper cells in the tumor microenvironment, researchers applied a chimeric antigen receptor that recognized human CXCR5 with high avidity.
[Nature Communications]

Full Article

Identification
of a Subset of Immunosuppressive P2RX1-Negative Neutrophils in Pancreatic Cancer Liver Metastasis

RNA sequencing of murine pancreatic ductal adenocarcinoma liver metastasis-infiltrated neutrophils show that P2RX1-deficient neutrophils express increased levels of immunosuppressive molecules, including PD-L1, and have enhanced mitochondrial metabolism.
[Nature Communications]

Full Article

CRISPR/Cas9
Directed to the Ube3a Antisense Transcript Improves Angelman Syndrome Phenotype in Mice

Scientists showed that gene editing of Ube3a-ATS in the mouse brain resulted in the formation of base pair insertions/deletions in neurons and the subsequent unsilencing of the paternal Ube3a allele in neurons, which partially corrected the behavior phenotype of a murine Angelman syndrome model.
[Journal of Clinical Investigation]

Abstract Full Article
Graphical Abstract

U2af1 Is Required for Survival and Function of Hematopoietic Stem/Progenitor Cells

Using a novel conditional U2af1 knockout allele, investigators found that deletion of U2af1 results in profound defects in hematopoiesis characterized by pancytopenia, ablation of hematopoietic stem/progenitor cells leading to bone marrow failure and early lethality in mice.
[Leukemia]

Abstract

A Modular and Controllable T Cell Therapy Platform for Acute Myeloid Leukemia

Researchers developed a modular and controllable MHC-unrestricted adoptive T cell therapy platform tailored to acute myeloid leukemia.
[Leukemia]

Full Article

Platelet-Targeted
Gene Therapy Induces Robust Immune Tolerance Even in a Primed Model via Peripheral Clonal Deletion of Antigen-Specific CD4 and CD8 T Cells and Expansion of Antigen-Specific Regulatory T Cells

Using the OT-I/WT model, the authors showed that antigen-specific CD8 T cells were partially deleted in recipients after platelet-targeted gene transfer.
[Molecular Therapy-Nucleic Acids]

Abstract Graphical Abstract

Zfp521
Is Essential for the Quiescence and Maintenance of Adult Hematopoietic Stem Cells under Stress

Scientists found that Zinc finger protein 521 (Zfp521) deletion did not inhibit adult hematopoiesis under homeostatic conditions. In contrast, Zfp521-null chimeric mice showed significantly reduced pool size of hematopoietic stem cells and hematopoietic progenitor cells associated with increased apoptosis and loss of quiescence.
[iScience]

Abstract Full Article
Graphical Abstract

Overcoming
Target Epitope Masking Resistance that Can Occur on Low-Antigen-Expresser AML Blasts after IL-1RAP Chimeric Antigen Receptor T Cell Therapy Using the Inducible Caspase 9 Suicide Gene Safety Switch

As acute myeloid leukemia (AML) primary blasts express different levels of accessory protein of the interleukin-1 receptor (IL-1RAP), scientists modeled transduction of different AML tumor cell lines screened for density of antigenic sites with their lentiviral vectors carrying a third-generation IL-1RAP chimeric antigen receptor, an iCASP9 suicide gene, and a truncated CD19 surface gene.
[Cancer Gene Therapy]

Full Article

New human primary cell products—frozen leukopaks, regulatory T cells, and more. Click to view products.

REVIEWS

CRISPR Technologies for Precise Epigenome Editing

The authors review the state of currently achievable epigenetic manipulations along with corresponding applications. With future optimization, CRISPR-based epigenomic editing stands as a set of powerful tools for understanding and controlling biological function.
[Nature Cell Biology]

Abstract

INDUSTRY AND POLICY NEWS

Adverum
Biotechnologies Completes Patient Enrollment for INFINITY Phase II Trial of ADVM-022 in DME and Provides 2021 Business Outlook

Adverum Biotechnologies, Inc. announced the completion of patient enrollment in the INFINITY Phase II trial to evaluate a single intravitreal injection of ADVM-022, for the treatment of diabetic macular edema.
[Adverum Biotechnologies, Inc.]

Press Release

FEATURED EVENT

Distinct
Developmental Pathways from Blood Monocytes Generate Human Lung Macrophage Diversity

CXCR5
CAR-T Cells Simultaneously Target B Cell Non-Hodgkin’s Lymphoma and Tumor-Supportive Follicular T Helper Cells

Identification
of a Subset of Immunosuppressive P2RX1-Negative Neutrophils in Pancreatic Cancer Liver Metastasis

CRISPR/Cas9
Directed to the Ube3a Antisense Transcript Improves Angelman Syndrome Phenotype in Mice

U2af1 Is Required for Survival and Function of Hematopoietic Stem/Progenitor Cells

A Modular and Controllable T Cell Therapy Platform for Acute Myeloid Leukemia

Platelet-Targeted
Gene Therapy Induces Robust Immune Tolerance Even in a Primed Model via Peripheral Clonal Deletion of Antigen-Specific CD4 and CD8 T Cells and Expansion of Antigen-Specific Regulatory T Cells

Zfp521
Is Essential for the Quiescence and Maintenance of Adult Hematopoietic Stem Cells under Stress

Overcoming
Target Epitope Masking Resistance that Can Occur on Low-Antigen-Expresser AML Blasts after IL-1RAP Chimeric Antigen Receptor T Cell Therapy Using the Inducible Caspase 9 Suicide Gene Safety Switch

CRISPR Technologies for Precise Epigenome Editing

Adverum
Biotechnologies Completes Patient Enrollment for INFINITY Phase II Trial of ADVM-022 in DME and Provides 2021 Business Outlook

ISSCR: Stem Cells and Global Sustainability

> See All Events

Postdoctoral Fellowship – Stem Cell Biology/Lung Biology

Research Lab Specialist – Genome Editing and Sickle Cell Disease

Postdoctoral Researcher – Single-Cell Immunology

Postdoctoral
Positions – Gene Regulation in Skeletal Muscle Stem Cells and Embryonic Stem Cells

Postdoctoral Fellow – Stem Cell Biology

> See All Jobs